2seventy bio is an emerging immuno-oncology company focused on developing transformative treatment options for people living with a range of difficult to treat cancers. The company has a robust cell therapy pipeline across a range of hematologic and solid tumors, with a unique scientific approach to delivering therapies that provide significant benefit to cancer patients.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

COM:2SEVENTYBIO

2seventy bio

Last Close

4.82

30/08 20:00

Market Cap

197.91M

Beta: -

Volume Today

221.87K

Avg: -

market

industry

website

crunchbase

ipo date

peer of

Metrics